Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Liabilities and Shareholders Equity (2016 - 2025)

Acro Biomedical has reported Liabilities and Shareholders Equity over the past 10 years, most recently at $14098.0 for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $14098.0 for Q4 2025, down 55.91% from a year ago — trailing twelve months through Dec 2025 was $96873.0 (down 41.9% YoY), and the annual figure for FY2025 was $14098.0, down 55.91%.
  • Liabilities and Shareholders Equity for Q4 2025 was $14098.0 at Acro Biomedical, up from $4323.0 in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ACBM hit a ceiling of $938874.0 in Q1 2021 and a floor of $4323.0 in Q3 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $298803.5 (2023), compared with a mean of $364818.5.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 97.04% in 2023 and later skyrocketed 103.27% in 2024.
  • Acro Biomedical's Liabilities and Shareholders Equity stood at $761077.0 in 2021, then dropped by 9.67% to $687486.0 in 2022, then tumbled by 91.5% to $58459.0 in 2023, then plummeted by 45.31% to $31974.0 in 2024, then plummeted by 55.91% to $14098.0 in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $14098.0 (Q4 2025), $4323.0 (Q3 2025), and $53277.0 (Q2 2025) per Business Quant data.